NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

View More View Less
  • 1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • 2 University of Washington/Seattle Cancer Care Alliance;
  • 3 Abramson Cancer Center at the University of Pennsylvania;
  • 4 University of Colorado Cancer Center;
  • 5 Huntsman Cancer Institute at the University of Utah;
  • 6 Fox Chase Cancer Center;
  • 7 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • 8 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • 9 The University of Texas MD Anderson Cancer Center;
  • 10 Dana-Farber/Brigham and Women’s Cancer Center;
  • 11 Duke Cancer Institute;
  • 12 Moffitt Cancer Center;
  • 13 O’Neal Comprehensive Cancer Center at UAB;
  • 14 Yale Cancer Center/Smilow Cancer Hospital;
  • 15 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • 16 UCSF Helen Diller Family Comprehensive Cancer Center;
  • 17 Roswell Park Comprehensive Cancer Institute;
  • 18 Vanderbilt-Ingram Cancer Center;
  • 19 Fred & Pamela Buffett Cancer Center;
  • 20 Massachusetts General Hospital Cancer Center;
  • 21 University of Wisconsin Carbone Cancer Center;
  • 22 University of Michigan Rogel Cancer Center;
  • 23 Stanford Cancer Institute;
  • 24 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • 25 UC San Diego Moores Cancer Center;
  • 26 City of Hope National Medical Center;
  • 27 Memorial Sloan Kettering Cancer Center;
  • 28 Mayo Clinic Cancer Center;
  • 29 St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; and
  • 30 National Comprehensive Cancer Network.
Restricted access

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:734.

  • 2.

    Howlader N, Noone AM, Krapcho M, . SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. Available at https://seer.cancer.gov/csr/1975_2016/. Based on November 2018 SEER data submission, posted to the SEER website, April 2019. Accessed October 20, 2019.

  • 3.

    Garon EB, Hellmann MD, Rizvi NA, . Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 2019;37:25182527.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Leighl NB, Hellmann MD, Hui R, . Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med 2019;7:347357.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Lin JJ, Cardarella S, Lydon CA, . Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol 2016;11:556565.

  • 6.

    Pacheco JM, Gao D, Smith D, . Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol 2019;14:691700.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Shaw AT, Riely GJ, Bang YJ, . Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019;30:11211126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Singhi EK, Horn L, Sequist LV, . Advanced non-small cell lung cancer: sequencing agents in the EGFR-mutated/ALK-rearranged populations. Am Soc Clin Oncol Educ Book 2019;39:e187197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Zhao D, Chen X, Qin N, . The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Sci Rep 2017;7:40374.

  • 10.

    Johung KL, Yeh N, Desai NB, . Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 2016;34:123129.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Reck M, Rodríguez-Abreu D, Robinson AG, . Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019;37:537546.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Antonia SJ, Borghaei H, Ramalingam SS, . Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019;20:13951408.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Drilon A, Laetsch TW, Kummar S, . Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731739.

  • 14.

    Solomon BJ, Besse B, Bauer TM, . Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018;19:16541667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Wu YL, Cheng Y, Zhou X, . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:14541466.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Gandhi L, Rodríguez-Abreu D, Gadgeel S, . Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:20782092.

  • 17.

    Socinski MA, Jotte RM, Cappuzzo F, . Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378:22882301.

  • 18.

    Paz-Ares L, Luft A, Vicente D, . Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379:20402051.

  • 19.

    Mok TS, Cheng Y, Zhou X, . Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol 2018;36:22442250.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Ettinger DS, Wood DE, Aggarwal C, . NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 7.2019. Accessed August 30, 2019. To view the most recent version, visit NCCN.org.

  • 21.

    Reck M, Rodríguez-Abreu D, Robinson AG, . Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:18231833.

  • 22.

    Mok TSK, Wu YL, Kudaba I, . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:18191830.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Lindeman NI, Cagle PT, Aisner DL, . Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 2018;142:321346.

    • Search Google Scholar
    • Export Citation
  • 24.

    Soria JC, Ohe Y, Vansteenkiste J, . Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113125.

  • 25.

    Lisberg A, Cummings A, Goldman JW, . A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol 2018;13:11381145.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Camidge DR, Dziadziuszko R, Peters S, . Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 2019;14:12331243.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Garassino M, Rodriguez-Abreu D, Gadgeel S, . Evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC [abstract]. J Thorac Oncol 2019;14:S216217. Abstract OA04.06.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Reck M, Mok TSK, Nishio M, . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 2019;7:387401.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Langer CJ, Gadgeel SM, Borghaei H, . Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:14971508.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Thatcher N, Goldschmidt JH, Thomas M, . Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res 2019;25:20882095.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Reinmuth N, Bryl M, Bondarenko I, . PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin), both plus paclitaxel and carboplatin, as first-line treatment of advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study. BioDrugs 2019;33:555570.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Melosky B, Reardon DA, Nixon AB, . Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol 2018;14:25072520.

  • 33.

    Weise M, Kurki P, Wolff-Holz E, . Biosimilars: the science of extrapolation. Blood 2014;124:31913196.

  • 34.

    Weise M, Bielsky MC, De Smet K, . Biosimilars: what clinicians should know. Blood 2012;120:51115117.

  • 35.

    Paz-Ares LG, Luft A, Tafreshi A, . Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab for patients with metastatic squamous non-small cell lung cancer [abstract]. J Clin Oncol 2018;36:Abstract 105.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 11288 11288 1075
PDF Downloads 4921 4921 514
EPUB Downloads 0 0 0